Northwest Biotherapeutics submits MAA to MHRA for DCVax-L

Northwest Biotherapeutics announced that a Marketing Authorization Application was submitted yesterday to the Medicines and Healthcare Products Regulatory Agency in the UK for DCVax-L for glioblastoma brain cancer. The MAA seeks approval for commercialization of DCVax-L for both newly diagnosed and recurrent glioblastoma. The application also requests to be considered under the MHRA’s rapid 150-day review pathway, which the agency has established for new medicines for serious unmet medical needs.